Tanvi Mehta

Manager, Regulatory Affairs and Policy

Tanvi Mehta came to Greenleaf with a background in finance and professional services and an understanding of the business of health care, which she applies to her work in regulatory affairs and policy. Prior to Greenleaf, she was responsible for client relations and financial reporting at Morgan Stanley and Invesco. Most recently, she worked for Arc Initiatives in Washington D.C., where she supported rollouts of various national campaigns with in-depth policy analysis, strategic communications, and regulatory assessments. Tanvi’s financial experience allows her to effectively address regulatory challenges with an analytical approach.

Throughout her education, Tanvi gained significant exposure to public health and policy. She received her business graduate degree with a focus on health care. During her MBA program, she served on the board of the Healthcare Business Association and participated in DC-based public policy initiatives.

Tanvi earned her MBA from Georgetown University’s McDonough School of Business and her B.A. in public health and economics from Agnes Scott College. 

Lisa Parks

Senior Vice President, Regulatory Policy

Lisa joined Greenleaf Health after serving for eight years as the Vice President of Sciences and Regulatory Affairs at the Association for Accessible Medicines (AAM), a leading generic and biosimilars trade association in Washington, D.C. In this role, she developed and promoted regulatory and scientific affairs initiatives, internal and external communications and relations, and training/knowledge-sharing opportunities for member companies. She was AAM’s primary liaison with the FDA and facilitated discussions and efforts with the FDA, lawmakers, and industry stakeholders on numerous topics that impacted the generic and biosimilar industry. Lisa served as the industry lead negotiator for the Generic Drug User Fee Amendment (GDUFA) II and III negotiations with the FDA and co-lead for the Biosimilars User Fee Act (BsUFA) II and III negotiations for AAM’s Biosimilars Council. She also led the implementation phase of both the GDUFA II and BsUFA II user fee programs for AAM.

Lisa’s career with the FDA’s Office of Generic Drugs (OGD) began in 2008 in the regulatory affairs division. Her keen ability to facilitate discussions and build consensus around intricate regulatory policy issues was quickly recognized by senior CDER leadership, and she was appointed to lead the implementation of GDUFA I for the OGD. Due to her accomplishments, CDER leadership appointed her for further work in planning for and standing up the Office of Pharmaceutical Quality and other modernization initiatives.

In 2022, Lisa launched Daedal Regulatory Strategies, LLC to assist entities in better interpreting and navigating discussions with the FDA on complex regulatory and policy issues. In August 2022, Lisa joined Greenleaf as the Senior Vice President of Regulatory Policy in order to work alongside fellow experts and former FDA colleagues in helping clients advance their interactions and dialogue with the Agency.

Lisa holds a pharmacy degree from the Massachusetts College of Pharmacy in Boston, MA. 

Sean Hilscher

Vice President, Regulatory Policy

Sean Hilscher brings more than 10 years of experience as a consultant in the international and U.S. health care markets to his role as Vice President of Regulatory Policy at Greenleaf Health. Prior to joining Greenleaf, Sean served as a Director at the American College of Cardiology (ACC), where he managed a suite of real-world evidence platforms marketed to providers, payers, and life science companies. In the role, Sean provided objective analyses of markets, assessing the market impact of policy and regulatory changes.

Prior to his work at ACC, Sean was a manager on the Clinical Sourcing team at the Advisory Board Company. As a manager, Sean led data analysis efforts for operational and supply chain consulting engagements with provider organizations across the country.

Sean earned his MBA from the Georgetown University McDonough School of Business and an MA in Politics, Philosophy, and Economics from the University of Oxford.

Stephen Mason

Executive Vice President, Regulatory Policy

Stephen Mason came to Greenleaf following an accomplished and diverse career that includes time in regulated industry, at the Food and Drug Administration (FDA), and on Capitol Hill.

Before joining Greenleaf, Stephen served as Director of Regulatory Affairs for Amgen. In this role, Stephen led the company’s US regulatory policy function, which included developing and implementing strategies for corporate engagement with regional and global regulatory agencies.

Stephen joined Amgen following 3 years as Assistant Commissioner of Legislation at FDA, where he managed all legislative and policy activities affecting the agency and Congress, including congressional oversight activities. Additionally, Stephen served as the primary liaison for FDA in its interactions with Congress, the White House, other federal departments, and state governments.

Stephen’s career also includes a role as Director of Government Relations at the Generic Pharmaceutical Association (GPhA). While serving at GPhA, Stephen was a leader in advocating for the association’s priorities in Congress and the Administration. He was instrumental in the development of generic drug policy issues, as well as in organizing coalition and outreach efforts surrounding federal policy issues.

Before joining GPhA, Stephen held several other positions, including Legislative Aide to Congressman John Ensign (R-NV). In this position, he directed legislative issue management and fostered policy development on an array of issues, including healthcare.

Stephen earned a B.A. in Business Administration-Finance at Oakland University in Rochester, MI.

Rhona Baniqued

Executive Director of Operations, Drug and Biological Products

Rhona Baniqued joined Greenleaf Health as Director of Operations, Drug and Biological Products in 2014, with more than 12 years’ experience as a marketing professional with a successful track record managing complex agency, corporate, and nonprofit programs. At Greenleaf, Rhona is responsible for managing multiple processes, including contracting, client relationship and general operations management of Greenleaf’s Drug and Biological Products Team.

Before joining Greenleaf, Rhona served as a District Marketing Manager for the Microsoft Corporation, based in Washington, DC. In this position, Rhona brought specific products and solutions to customers by working with diverse sales, service, and partner organizations to build the “sales pipeline.” She developed a marketing strategy focused on an application platform by identifying leads and revenue growth opportunities that accelerated sales while remaining sensitive to customer insights and business and competitive trends. Her efforts contributed to application pipeline sales in excess of $17M. In addition, Rhona directed the execution of the Executive Circle program, focused on building or strengthening relationships between Microsoft and corporate senior executives. Early in her career at Microsoft, Rhona administered the partner readiness program, in conjunction with corporate initiatives to train partners on Go-To-Market campaigns. Rhona’s attendance ratios at these programs consistently ranked among those of the top 25 cities globally.

Before her work at Microsoft, Rhona served as Senior Media Planner at Arnold Communications, developing and managing the implementation of long-term strategic media buys across print, radio, television, out-door, and on-line media for many Fortune 500 clients.

Rhona began her career on Capitol Hill, working on legislative issues for Congressman Owen Pickett, D-Va.

Rhona received her undergraduate degree from George Mason University.

5 records